Top 10 Best-Selling Drugs 2026

Thanks to booming sales of blockbuster obesity and diabetes treatments, the amount that Americans spent on prescription drugs this year is on track to surpass $1 trillion, according to a report released in April by the American Society of Health-System Pharmacists (ASHP).

That would be a sharp, above-inflation 9.3% increase from the $915 billion in U.S. drug sales recorded last year, one of the fastest one-year percentage jumps ever recorded by the group. That 12.7% jump is higher than the one-year increases achieved by healthcare costs, and growth in the overall economy.

Even more eye-opening: Nearly one-third of prescription drug spending growth came from the $132 billion spent on a single category, namely glucagon-like peptide 1 (GLP-1) receptor agonists indicated for obesity/wight management and for type 2 diabetes.

“GLP-1s have fundamentally reshaped the drug-spending landscape,” Eric Tichy, PharmD, MBA, lead author of the report and division chair of supply chain management at Mayo Clinic. “And we are still on the steep part of the curve.”

According to ASHP, the 2025 and projected 2026 leaps in drug spending reflect more medications being used by more patients, with spending growth being predicted to range from 10–12% overall.

That would appear to explain the robust increases in sales by every one of the top 10 best-selling prescription drugs (based on 2025 sales) featured in this GEN A-List. Top-selling drugs are ranked based on sales or revenue reported for 2025 by biopharma companies in press announcements, annual reports, investor materials, and/or conference calls. Each drug is listed by name, sponsor(s), 2025 sales, 2024 sales, and the percentage change between those years.

The total 2025 aggregate value of the top 10 best-selling drugs was $188.136 billion, up 21.5% from $154.888 billion in 2024—and more than double (up 127.5% over 10 years from the $82.694 billion generated by 2016’s top 10 sellers, as reported by GEN.

Just missing the top 10 at #11 was Novo Nordisk’s Wegovy^®, the glucagon-like peptide 1 (GLP-1) receptor agonist indicated for weight loss in obese or overweight adults. Treatments ranked number 11 through number 15 in 2025 generated between approximately $8.4 billion and $12.2 billion in revenues. In addition to Wegovy, best sellers Nos. 12-15 include:

• Opdivo^® and its subcutaneous injection version Opdivo Qvantig (nivolumab / nivolumab and hyaluronidase-nvhy), marketed by Bristol Myers Squibb (BMS) worldwide except Japan, South Korea, and Taiwan, where Ono Pharmaceutical markets the drug.
• Trikafta^® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) from Vertex Pharmaceuticals, which markets the drug outside the U.S. as Kaftrio^®.
• Ocrevus^® (ocrelizumab) from Roche and its U.S. subsidiary Genentech.
• Farxiga^® (dapagliflozin), from AstraZeneca, which markets the drug outside the U.S. as Forxiga^®

Three drugs that ranked between #11 and #15 on last year’s A-List based on 2024 sales placed lower this year: Eylea/Eylea HD (aflibercept) from Regeneron Pharmaceuticals and Bayer, which ranked No. 17 in 2025 sales; Gardasil/Gardasil 9 (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant/Human Papillomavirus 9-valent Vaccine, Recombinant) from Merck & Co., now No. 27; and Humira^® (adalimumab) from AbbVie, which had long been the top-selling drug for years until being surpassed by Keytruda^® but is now No. 32.

Eylea and Humira now face competition from biosimilars, while Merck halted Gardasil shipments to China last year, citing declining sales.

1. Keytruda^® / Keytruda Qlex ¹

(pembrolizumab / pembrolizumab and berahyaluronidase alfa-pmph) Merck & Co.

2025 Sales: $31.680 billion ¹

2024 Sales: $29.482 billion

% Change: +7.5%

2. Mounjaro^®

(tirzepatide) Eli Lilly

2025 Sales: $22.965 billion

2024 Sales: $11.540 billion

% Change: +99.0%

3. Eliquis^®

(apixaban) Bristol Myers Squibb and Pfizer

2025 Sales: $22.404 billion ($14.443 billion BMS + $7.961 billion Pfizer)

2024 Sales: $20.699 billion ($13.333 billion BMS + $7.366 billion Pfizer)

% Change: +8.2%

4. Ozempic^®

(semaglutide) Novo Nordisk

2025 Sales: $19.611 billion (DKK 127.089 billion)

2024 Sales: $18.570 billion ² (DKK 120.342 billion)

% Change: +5.6%

5. Dupixent^®

(dupilumab)³ Sanofi and Regeneron Pharmaceuticals

2025 Sales: $18.124 billion (€15.714 billion)

2024 Sales: $15.077 billion ⁴ (€13.072 billion)

% Change: +20.2%

6. Skyrizi^®

(risankizumab-rzaa) AbbVie

2025 Sales: $17.562 billion

2024 Sales: $11.718 billion

% Change: +49.9%

7. Darzalex^® / Darzalex Faspro^®

(daratumumab / daratumumab and hyaluronidase-fihj) Johnson & Johnson and Genmab ⁵

2025 Sales: $14.351 billion ⁵

2024 Sales: $11.670 billion ⁵

% Change: +23.0%

8. Biktarvy^®

(bictegravir, emtricitabine, and tenofovir alafenamide) Gilead Sciences

2025 Sales: $14.334 billion

2024 Sales: $13.423 billion

% Change: +6.8%

9. Jardiance family

(empagliflozin, monotherapy and in combinations with linagliptin and metformin) ⁶ Boehringer Ingelheim and Eli Lilly

2025 Sales: $13.563 billion ($10.132 billion [€8.785 billion] Boehringer Ingelheim + $3.431 billion Eli Lilly] ⁶

2024 Sales: $12.979 billion ($9.638 billion [€8.357 billion] Boehringer Ingelheim + $3.341 billion Eli Lilly) ⁶

% Change: +4.5%

10. Zepbound^®

(tirzepatide) Eli Lilly

2025 Sales: $13.542 billion

2024 Sales: $4.926 billion

% Change: +174.9%

References

1. Starting in 2025, Merck combined into a single figure the sales of Keytruda (pembrolizumab) and Keytruda Qlex, a subcutaneous injectable immunotherapy consisting of pembrolizumab and berahyaluronidase alfa, and which like Keytruda is indicated to treat multiple types of cancer.
2. Figure differs from the $18.655 billion reported by GEN in last year’s A-List of Top 10 Best-Selling Drugs due to currency fluctuations.
3. Sanofi records global net product sales of Dupixent, with each company recording its half-share of profits on global sales of the drug.
4. Figure differs from the $15.125 billion reported by GEN in last year’s A-List of Top 10 Best-Selling Drugs due to currency fluctuations.
5. All sales figures are recorded by Johnson & Johnson, with Genmab receiving royalties on worldwide sales from J&J. Genmab does not disclose specific royalty revenues for Darzalex and Darzalex Faspro but has furnished a 2025 royalty figure for the treatments of $2.443 billion, up 12.5% from DKK 13.922 billion ($2.172 billion) in 2024. Genmab changed its reporting and functional currency to U.S. dollars from Danish kroner as of 2025.
6.  Lilly includes revenues from Glyxambi^® (empagliflozin/linagliptin), Synjardy^® (empagliflozin/metformin hydrochloride), and Trijardy® XR (empagliflozin, linagliptin, and metformin hydrochloride) in its revenue figures for the Jardiance family—which includes net product revenue as well as collaboration and other revenue.
7.  Figure differs from the $12.832 billion in 2024 sales reported by GEN in last year’s A-List of Top 10 Best-Selling Drugs due to currency fluctuations.

The post Top 10 Best-Selling Drugs 2026 appeared first on GEN - Genetic Engineering and Biotechnology News.